A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Lone Tree Medical Center
University of Colorado Hospital
Study ID
Protocol Number: 17-0500
More information available at ClinicalTrials.gov: NCT03005782
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers